Safety and pharmacokinetics of milademetan, a MDM2 inhibitor, in Japanese patients with solid tumors: A phase I study
…, K Nakano, T Shimizu, J Tomomatsu… - Cancer …, 2021 - Wiley Online Library
Milademetan (DS‐3032, RAIN‐32) is an orally available mouse double minute 2 (MDM2)
antagonist with potential antineoplastic activity owing to increase in p53 activity through …
antagonist with potential antineoplastic activity owing to increase in p53 activity through …
[HTML][HTML] Clinicopathological and genomic features in patients with head and neck neuroendocrine carcinoma
…, K Nakano, M Yunokawa, M Ono, J Tomomatsu… - Modern Pathology, 2021 - Elsevier
Neuroendocrine carcinoma (NEC) of the head and neck is a rare type of malignancy,
accounting for only 0.3% of all head and neck cancers, and its clinicopathological and genomic …
accounting for only 0.3% of all head and neck cancers, and its clinicopathological and genomic …
Sequential analysis of neutrophil-to-lymphocyte ratio for differentiated thyroid cancer patients treated with lenvatinib
…, M Nishizawa, M Yunokawa, M Ono, J Tomomatsu… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Neutrophil-to-lymphocyte ratio (NLR) has been reported to be associated
with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR…
with poor prognosis for radioactive iodine ablation refractory differentiated thyroid cancer (RR…
Efficacy of paclitaxel-based chemotherapy after progression on nivolumab for head and neck cancer
…, T Urasaki, A Ohmoto, K Nakano, M Ono, J Tomomatsu… - in vivo, 2021 - iv.iiarjournals.org
Background/Aim: In the CheckMate-141 trial regarding head and neck cancer (HNC),
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …
nivolumab conferred a survival benefit to patients. However, the best treatment sequence of …
[HTML][HTML] Risk factors for pneumothorax in advanced and/or metastatic soft tissue sarcoma patients during pazopanib treatment: a single-institute analysis
K Nakano, N Motoi, J Tomomatsu, T Gokita, K Ae… - BMC cancer, 2016 - Springer
Background After the approval of pazopanib for the treatment of soft tissue sarcoma (STS),
pneumothorax was reported as an unexpected adverse event during pazopanib treatment. …
pneumothorax was reported as an unexpected adverse event during pazopanib treatment. …
Neutrophil-to-lymphocyte ratio as a prognostic marker for anaplastic thyroid cancer treated with lenvatinib
…, Y Sato, K Nakano, M Yunokawa, M Ono, J Tomomatsu… - in vivo, 2020 - iv.iiarjournals.org
Background/Aim: Lenvatinib is one of the few options for patients with anaplastic thyroid cancer
(ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this …
(ATC). However, tumor markers for ATC treated with lenvatinib is lacking. The aim of this …
[HTML][HTML] Pre-treatment neutrophil-to-lymphocyte ratio (NLR) as a predictive marker of pazopanib treatment for soft-tissue sarcoma
…, N Hayashi, M Yunokawa, M Ono, J Tomomatsu… - Cancers, 2021 - mdpi.com
Simple Summary Second-line systematic therapy options for soft-tissue sarcoma (STS)
have remained unchanged for decades due to the rarity and various histological types …
have remained unchanged for decades due to the rarity and various histological types …
[HTML][HTML] Phase I study of ipatasertib as a single agent and in combination with abiraterone plus prednisolone in Japanese patients with advanced solid tumors
T Doi, Y Fujiwara, N Matsubara, J Tomomatsu… - Cancer Chemotherapy …, 2019 - Springer
Purpose Ipatasertib is a selective inhibitor of Akt, a frequently activated protein kinase in
human cancers. The current study assessed the safety, tolerability, and pharmacokinetics of …
human cancers. The current study assessed the safety, tolerability, and pharmacokinetics of …
Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor‐positive advanced breast cancer
…, T Kobayashi, K Nakano, J Tomomatsu… - Cancer …, 2018 - Wiley Online Library
Taselisib is a potent and selective phosphatidylinositide 3‐kinase ( PI 3K) inhibitor. The
present article reports the first study of taselisib administration in Japanese patients. The aim of …
present article reports the first study of taselisib administration in Japanese patients. The aim of …
A comparison of weekly paclitaxel and cetuximab with the EXTREME regimen in the treatment of recurrent/metastatic squamous cell head and neck carcinoma
K Nakano, S Marshall, S Taira, Y Sato, J Tomomatsu… - Oral oncology, 2017 - Elsevier
Background The effectiveness of the combination chemotherapy of weekly paclitaxel and
cetuximab has not yet been compared to that of the current standard regimen, EXTREME (…
cetuximab has not yet been compared to that of the current standard regimen, EXTREME (…